Jyseleca

Filgotinib, the active ingredient in Jyseleca, is a Janus kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and ulcerative colitis in adult patients. GNH USA supplies Jyseleca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jyseleca is a selective JAK1 inhibitor used in inflammatory disease management.

Rheumatoid arthritis: reduces disease activity and slows joint damage in adults. Ulcerative colitis: induces clinical remission and promotes mucosal healing in adults.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection - Diarrhea - Elevated liver enzymes (ALT/AST) - Increased cholesterol levels

Serious or Rare Side Effects: - Serious infections (e.g., tuberculosis, opportunistic infections) - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Hepatotoxicity (severe liver injury) - Malignancies (lymphoma, other cancers) - Gastrointestinal perforation

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

Monitor liver function: perform baseline and periodic ALT/AST testing. Screen for infections: evaluate for active tuberculosis or chronic infections. Assess cardiovascular risk: consider history of thrombosis before use. Vaccination guidance: avoid live vaccines during treatment. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Filgotinib may interact with other medicines that affect its metabolism or immune function.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase filgotinib exposure. - Live vaccines: heightened risk of infection. - Immunosuppressants (e.g., high‑dose corticosteroids): additive infection risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise drug levels. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Vaccines (inactivated): assess timing relative to therapy.